Corteva (NYSE:CTVA) Stock Price Expected to Rise, Mizuho Analyst Says

Corteva (NYSE:CTVA) had its price target raised by equities researchers at Mizuho from $94.00 to $96.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s target price points to a potential upside of 14.09% from the company’s current price.

Other research analysts have also recently issued reports about the company. Berenberg Bank lifted their price target on Corteva from $68.00 to $78.00 and gave the company a “hold” rating in a report on Thursday, March 26th. Morgan Stanley raised their price target on shares of Corteva from $84.00 to $95.00 and gave the company an “overweight” rating in a report on Thursday, May 28th. Royal Bank Of Canada increased their price objective on Corteva from $95.00 to $97.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. CICC Research raised their price target on Corteva from $80.00 to $93.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Corteva from $90.00 to $100.00 in a research report on Monday, May 11th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Corteva currently has a consensus rating of “Moderate Buy” and an average price target of $88.90.

Corteva Trading Up 0.7%

Shares of Corteva stock opened at $84.14 on Thursday. The firm has a market capitalization of $56.28 billion, a PE ratio of 48.98, a price-to-earnings-growth ratio of 2.59 and a beta of 0.55. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.47 and a quick ratio of 1.03. Corteva has a 52-week low of $60.53 and a 52-week high of $85.95. The company’s fifty day moving average price is $79.57 and its two-hundred day moving average price is $76.66.

Corteva (NYSE:CTVA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.32. Corteva had a return on equity of 9.95% and a net margin of 6.50%.The company had revenue of $4.91 billion for the quarter, compared to analyst estimates of $4.64 billion. During the same period in the prior year, the company posted $1.13 EPS. The company’s revenue was up 11.0% compared to the same quarter last year. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, analysts expect that Corteva will post 3.72 EPS for the current year.

Institutional Investors Weigh In On Corteva

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPL Wealth Management LLC bought a new position in shares of Corteva during the 3rd quarter worth approximately $25,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Corteva in the fourth quarter worth $27,000. Bank of Jackson Hole Trust acquired a new position in Corteva during the fourth quarter worth $28,000. Cornerstone Financial Management LLC bought a new position in Corteva in the fourth quarter valued at $29,000. Finally, Basepoint Wealth LLC acquired a new stake in Corteva in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.